Stallergenes Welcomes Ares Life Sciences as a New Reference Shareholder

November 10, 2010

ANTONY, France, November 10, 2010 /PRNewswire-FirstCall/ — Following the
announcement that Wendel had entered exclusive negotiations with Ares Life
Sciences on October 28, 2010, with a view to selling its entire stake (around
46%) in Stallergenes, the company’s Works Council met on November 10, 2010.

Stallergenes’ Works Council having returned a positive consultative
opinion at this meeting, Wendel and Ares Life Sciences proceeded to sign a
firm transfer agreement.

It is in this context that the Stallergenes Board of Directors met today.
It took note of Ares Life Sciences’ intention to pursue the development of
Stallergenes from the company’s French industrial footprint (production units
and R&D centre in Antony and Amilly), accelerate the execution of the
company’s strategic roadmap, as well as further support its international
development, notably in the US. The Stallergenes Board of Directors took also
note that Ares Life Sciences does not foresee any change within Stallergenes’
jobs, salary or human resources policies.

During the meeting, Stallergenes’ Chairman and CEO, Albert Saporta, has
declared: “The Ares Life Sciences team, which has already enjoyed some major
successes on the European and American pharmaceutical markets, has a thorough
understanding of the issues related to our sector and supports our
entrepreneurial vision. This expertise will be of great benefit to the
company in its current expansion phase”.

The Board of Directors also took note of the resignation of four of its
directors (Messrs. David Darmon, Arnaud Fayet, Dirk-Jan Van Ommeren and
Compagnie Financiere de la Trinite) and decided to co-opt Mrs Paola Ricci and
Messrs Jacques Theurillat, Patrick Lee, and Christian Chavy to replace them.
These changes of board directors remain subject to the completion of the sale
of Wendel’s stakeholding in Stallergenes to Ares Life Sciences.

Given the absence of any conflict of interest with respect to the planned
sale, the Board members also decided to appoint the accountancy firm Ledouble
SA as an independent expert with a view to issuing a fairness opinion in the
context of the takeover bid that Ares Life Sciences will submit regarding the
totality of Stallergenes’ shares in application of the regulations in force.
This appointment will come into force on the date of transfer of Wendel’s

Stallergenes and Ares Life Sciences’ management teams will hold a joint
telephone conference on Wednesday November 17 at 6 p.m. to answer questions
related to this change in shareholding.

In application of the provisions of the AMF’s General Regulations, the
Board of Directors may publish its opinion on the value of the said takeover
bid or its consequences for Stallergenes, its shareholders and its employees
on the internet once the planned bid has been submitted to the market

About Stallergenes

Stallergenes is a European biopharmaceutical company dedicated to
immunotherapy treatments for the prevention and treatment of allergy-related
respiratory diseases, such as allergic rhinoconjunctivitis, rhinitis and

A pioneer and leader in sublingual immunotherapy treatments, Stallergenes
dedicates more than 20% of its turnover, in gross terms, to Research and
Development and is actively involved in the development of a new therapeutic
class: sublingual immunotherapy tablets. In 2009, Stallergenes had a turnover
of 193 million euros and more than 500,000 patients were treated with
Stallergenes’ immunotherapy products.

    Euronext Paris (Compartment B)
    SBF 120.
    ISIN code: FR0000065674
    Reuters code: GEN.PA
    Bloomberg code: GEN.FP

    For further information, please visit our website:


SOURCE Stallergenes

Source: newswire

comments powered by Disqus